Elicio Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2025, on May 13, 2025. The company announced a net loss of $11.2 million for the quarter, a slight improvement from $11.8 million in the first quarter of 2024. The net loss per share for the first quarter of 2025 was $0.87, compared to $1.15 for the same period in the prior year.
Research and development (R&D) expenses for the first quarter of 2025 were $7.8 million, a modest increase from $7.6 million in the first quarter of 2024, primarily due to clinical trial expenses for the ongoing Phase 2 AMPLIFY-7P study. General and administrative (G&A) expenses also increased to $3.0 million from $2.7 million, mainly due to higher compensation and benefit costs.
As of March 31, 2025, Elicio had $18.4 million in cash and cash equivalents. The company projects that its current cash position will fund operations into the fourth quarter of 2025, extending beyond the anticipated Phase 2 AMPLIFY-7P interim analysis. Elicio continues to progress towards this interim analysis, expected in Q3 2025, and maintains alignment with the FDA on key design elements for a planned Phase 3 study of ELI-002.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.